Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer

Summary

A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The patients were randomly divided into the WLS-intervention group and the control group. The two groups of patients were given the most appropriate medication according to the specific conditions of the disease. Patients in the intervention group received additional oral administration of Weileshu, a probiotics product (Tongchuang Biotechnology).

Timeline

Start

2019-07-11

Primary completion

2021-10-30

Completion

2021-10-30

Drugs

Indications